Venlor Xr
1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 5656.
Registration
- Applicants
- 1
- Registrations
- 9
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Venlor xr 225 MG tablet EACH TABLET CONTAINS VENLAFAXINE HYDROCHLORIDE EQUIVALENT TO VENLAFAXINE 225,0 mg | 225 mgTablet | 56003556/1.2/0035 | Registrered | S5 | None |
| Venlor xr 300 MG tablet EACH TABLET CONTAINS VENLAFAXINE HYDROCHLORIDE EQUIVALENT TO VENLAFAXINE 300,0 mg | 300 mgTablet | 56003656/1.2/0036 | Registrered | S5 | None |
| Venlor xr 37,5 MG tablet EACH TABLET CONTAINS VENLAFAXINE HYDROCHLORIDE EQUIVALENT TO VENLAFAXINE 37,5 mg | 37,5 mgTablet | 56003756/1.2/0037 | Registered | S5 | None |
| Venlor xr 75 MG tablet EACH TABLET CONTAINS VENLAFAXINE HYDROCHLORIDE EQUIVALENT TO VENLAFAXINE 75,0 mg | 75 mgTablet | 56003856/1.2/0038 | Registered | S5 | None |
| Venlor xr 150 MG tablet EACH TABLET CONTAINS VENLAFAXINE HYDROCHLORIDE EQUIVALENT TO VENLAFAXINE 150,0 mg | 150 mgTablet | 56003956/1.2/0039 | Registered | S5 | None |
| Venlor xr 225 EACH CAPSULE CONTAINS: VENLAFAXINE HYDROCHLORIDE EQUIVALENT TO: VENLAFAXINE 225,0 mg | 225Extended-release capsules | 59021259/1.2/0212Approved 7 November 2024 | Registered | S5 | PIPIL |
| Venlor xr 37,5 EACH CAPSULE CONTAINS VENLAFAXINE 37,5 mg | 37,5Extended-release capsules. | A400032A40/1.2/0032Approved 7 November 2024 | Registered | S5 | PIPIL |
| Venlor xr 75 EACH CAPSULE CONTAINS VENLAFAXINE 75,0 mg | 75Extended-release capsules | A400033A40/1.2/0033Approved 7 November 2024 | Registered | S5 | PIPIL |
| Venlor xr 150 EACH CAPSULE CONTAINS VENLAFAXINE 150,0 mg | 150Extended-release capsules | A400034A40/1.2/0034Approved 7 November 2024 | Registered | S5 | PIPIL |
Regulatory status
Where S5 sits on the scale
Prescription-only, with tighter controls on repeats.
Schedule 5 medicines need a prescription, and repeat dispensing is capped at six months in total; the prescriber must state upfront how many times, and at what intervals, it may be repeated. Extra limits apply to some uses: if it is being used for its anxiolytic, antidepressant, tranquillising or analgesic properties, it cannot be prescribed for longer than six months without a further consultation. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S5, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it.
Consolidated Schedules listings for Venlafaxine hydrochloride equivalent to venlafaxine
S5: Venlafaxine
Consolidated Schedules 06 July 2026, line 9761
Pharmacological class: Psychoanaleptics (antidepressants). (class 1.2)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
Schedule Verification
Venlor xr 225, Cipla Medpro (Pty) Ltd is scheduled S5 in its official SAHPRA documents, read with 90% confidence.
These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.